CAJ | 학술논문

目的：探讨曲克芦丁脑蛋白水解物治疗眼前部缺血的临床效果。方法选择2013年1月~2015年1月于衡水市第二人民医院眼科就诊的120例眼前部缺血的患者作为研究对象，按照随机数字表法分为对照组和观察组，每组各60例。对照组患者给予扩张血管、肌注眼氨肽和安妥碘治疗，而观察组则在上述治疗的基础上加用曲克芦丁脑蛋白水解物治疗，两组均连续静脉滴注2周，观察两组患者的临床治疗有效率及患者对治疗的满意度。结果观察组显效48例，有效10例，无效2例，总有效率（90.6%）明显优于对照组（显效33例，有效16例，无效11例，总有效率为75.0%），两组总有效率比较差异有高度统计学意义（P<0.01）。观察组患者满意30例，基本满意18例，不满意12例，满意率为80.0%；对照组患者满意16例，基本满意23例，不满意21例，满意率为65.0%；观察组满意率明显高于对照组，差异有统计学意义（P<0.05）。结论眼前部缺血患者在给予扩血管药物治疗的同时加用曲克芦丁脑蛋白水解物，可以很好地缓解临床症状，提高患者满意度，减少医疗纠纷的发生，值得推广。
목적：탐토곡극호정뇌단백수해물치료안전부결혈적림상효과。방법선택2013년1월~2015년1월우형수시제이인민의원안과취진적120례안전부결혈적환자작위연구대상，안조수궤수자표법분위대조조화관찰조，매조각60례。대조조환자급여확장혈관、기주안안태화안타전치료，이관찰조칙재상술치료적기출상가용곡극호정뇌단백수해물치료，량조균련속정맥적주2주，관찰량조환자적림상치료유효솔급환자대치료적만의도。결과관찰조현효48례，유효10례，무효2례，총유효솔（90.6%）명현우우대조조（현효33례，유효16례，무효11례，총유효솔위75.0%），량조총유효솔비교차이유고도통계학의의（P<0.01）。관찰조환자만의30례，기본만의18례，불만의12례，만의솔위80.0%；대조조환자만의16례，기본만의23례，불만의21례，만의솔위65.0%；관찰조만의솔명현고우대조조，차이유통계학의의（P<0.05）。결론안전부결혈환자재급여확혈관약물치료적동시가용곡극호정뇌단백수해물，가이흔호지완해림상증상，제고환자만의도，감소의료규분적발생，치득추엄。
Objective To investigate the clinical effect of Troxerutin Cerebroprotein Hydrolysate Injection in the treatment of anterior segment ischemia. Methods From January 2013 to January 2015, in Department of Ophthalmology, Hengshui Second People's Hospital, 120 patients with anterior segment ischemic were selected, according to random number table, they were divided into observation group and control group, with 60 cases in each group. Control group was treated with dilating blood vessels, intramuscular injection of Ocular Extractives and Prolonium Iodide;observation group was treated with Troxerutin Cerebroprotein Hydrolysate based on control group, two groups received continuous intravenous infusion for 2 weeks. The clinical effective rate and satisfaction to treatment of two groups were observed. Results Both groups achieved a certain curative effect, in observation group, 48 cases were markedly effective, 10 cases were effective, 2 cases were invalid, the total effective rate was 90.6%, which were significantly better than those in control group (33 cases were markedly effective, 16 cases were effective, 14 cases were invalid, the total effective rate was 75.0%), the difference was statistically significant (P< 0.01). In observation group, 30 patients were satisfied, 18 patients were approximately satisfied, 12 patients were not satisfied, the satisfaction rate was 80.0%; in control group, 16 patients were satisfied, 23 patients were approximately satisfied, 21 patients were not satisfied, the satisfaction rate was 65.0%, the satisfaction rate in observation group was higher than that in control group, the difference was statistically significant (P < 0.05). Conclusion Troxerutin Cerebroprotein Hydrolysate based on vasodilator drug in the treatment of anterior segment ischemia can relieve clinical symptoms of anterior ischemia, improve patients' satisfaction and reduce occurrence of medical disputes, it is worthy of promotion.